FR2140126B1 - - Google Patents

Info

Publication number
FR2140126B1
FR2140126B1 FR7219501A FR7219501A FR2140126B1 FR 2140126 B1 FR2140126 B1 FR 2140126B1 FR 7219501 A FR7219501 A FR 7219501A FR 7219501 A FR7219501 A FR 7219501A FR 2140126 B1 FR2140126 B1 FR 2140126B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7219501A
Other versions
FR2140126A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Pharmaceuticals International Inc USA
Original Assignee
ICN Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICN Pharmaceuticals Inc filed Critical ICN Pharmaceuticals Inc
Publication of FR2140126A1 publication Critical patent/FR2140126A1/fr
Application granted granted Critical
Publication of FR2140126B1 publication Critical patent/FR2140126B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
FR7219501A 1971-06-01 1972-05-31 Expired FR2140126B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14901771A 1971-06-01 1971-06-01
US24025272A 1972-03-31 1972-03-31

Publications (2)

Publication Number Publication Date
FR2140126A1 FR2140126A1 (fr) 1973-01-12
FR2140126B1 true FR2140126B1 (fr) 1976-04-16

Family

ID=26846393

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7219501A Expired FR2140126B1 (fr) 1971-06-01 1972-05-31

Country Status (28)

Country Link
US (1) US3798209A (fr)
JP (5) JPS5527076B1 (fr)
AR (1) AR199463A1 (fr)
AU (1) AU461900B2 (fr)
BE (1) BE784195A (fr)
BG (1) BG22827A3 (fr)
CA (1) CA997756A (fr)
CH (1) CH614452A5 (fr)
DD (1) DD99791A5 (fr)
DE (1) DE2220246A1 (fr)
DK (2) DK143069C (fr)
EG (1) EG11406A (fr)
ES (1) ES403142A1 (fr)
FR (1) FR2140126B1 (fr)
GB (1) GB1353565A (fr)
HK (1) HK23876A (fr)
HU (1) HU167614B (fr)
IE (1) IE36478B1 (fr)
IL (1) IL39416A (fr)
IN (1) IN142290B (fr)
IS (1) IS913B6 (fr)
LU (1) LU65446A1 (fr)
MC (1) MC921A1 (fr)
MY (1) MY7600203A (fr)
NL (1) NL7207156A (fr)
NO (1) NO138805C (fr)
RO (1) RO62435A (fr)
SE (3) SE405604B (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
DE2401449A1 (de) * 1973-01-16 1974-07-25 Voorhees Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
US3888843A (en) * 1973-06-12 1975-06-10 Toyo Jozo Kk 4-carbamoyl-1-' -d-ribofuranosylimidazolium-5-olate
AR207138A1 (es) * 1974-03-18 1976-09-15 Icn Pharmaceuticals Metodo para la obtencion de 1,2,4-triazoles n-substituidos y sus sales de adicion
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US3960836A (en) * 1974-07-22 1976-06-01 Eli Lilly And Company Acylated derivatives of pyrazofurin and process for their preparation
US4007198A (en) * 1975-05-01 1977-02-08 American Cyanamid Company Substituted 1,2,4-triazole carboxamide
US4138547A (en) * 1977-12-22 1979-02-06 Icn Pharmaceuticals, Inc. Process for preparing 1,2,4-triazole nucleosides
JPS57146593A (en) * 1981-03-09 1982-09-10 Ajinomoto Co Inc Preparation of ribofuranosyltriazole derivative
US4451648A (en) * 1981-08-19 1984-05-29 The United States Of America As Represented By The Department Of Health And Human Services Process for the production of 2-β-D-ribofuranosylthiazole-4-carboxamide
US4531001A (en) * 1982-03-23 1985-07-23 Brigham Young University 2-β-D-ribofuranosylselenazole-4-carboxamide compounds
US4446315A (en) * 1982-09-24 1984-05-01 The United States Of America As Represented By The Department Of Health And Human Services Adenosine 5'-triphosphate-4-carboxamide-ribofuranosylthiazole
JPS5964648U (ja) * 1982-10-22 1984-04-28 阿波野　政晴 日覆用骨格
BE902199A (fr) * 1984-10-29 1985-07-31 Vira Tek Inc Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1, 2,4-triazole-3-carboxamide.
NZ213370A (en) * 1985-01-16 1989-03-29 Vira Tek Inc Method of treating viral infections of selected trees and field crops using ribavirin (1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide) or the 2,3,5-triacetyl or 5'-butyryl derivative thereof
DE3606634A1 (de) * 1986-02-28 1987-09-03 Mack Chem Pharm Isohexid-nucleoside, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3650505T2 (de) * 1986-03-27 1996-09-19 Gensia Inc AICA riboside zur prophylaktischen Behandlung von Krankheiten mit einer verminderten Durchblutung.
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
US5438131A (en) * 1992-09-16 1995-08-01 Bergstrom; Donald E. 3-nitropyrrole nucleoside
SK8612002A3 (en) * 1999-12-23 2003-03-04 Ribapharm Inc Compositions and methods for L-nucleosides, L-nucleotides, and their analogs
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
US7638496B2 (en) * 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (zh) * 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
US6815542B2 (en) * 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
CZ2003460A3 (cs) * 2000-08-22 2003-10-15 Ribapharm Inc. Způsob zvýšení selektivity, snížení cytoxicity a dávky léčebného prostředku
AU2002227252A1 (en) * 2000-12-01 2002-06-11 Cornell Research Foundation Animal model for flaviviridae infection
US20040014696A1 (en) * 2000-12-07 2004-01-22 Johnson Lau Specificity in treatment of diseases
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
DE60101056T2 (de) * 2001-07-30 2004-05-19 Clariant Life Science Molecules (Italia) S.P.A., Origgio Verfahren zur Herstellung von Ribavirin
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
CN1585631A (zh) * 2001-11-02 2005-02-23 桑多斯公司 制备快速溶解的高填量利巴韦林组合物的方法
KR100411398B1 (ko) 2001-12-06 2003-12-18 주식회사유한양행 베타-디-리보푸라노즈 유도체의 제조방법
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
US20040067877A1 (en) * 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
US7538094B2 (en) * 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
CA2506129C (fr) 2002-11-15 2015-02-17 Idenix (Cayman) Limited Nucleoside a ramification en 2' et mutation de flaviviridae
EP2319853B1 (fr) * 2002-12-12 2014-03-12 IDENIX Pharmaceuticals, Inc. Procédé de production de nucléosides ramifiés en 2'
KR20050110611A (ko) * 2002-12-23 2005-11-23 이데닉스 (케이만) 리미티드 3'-뉴클레오사이드 프로드럭의 생산 방법
MXPA05010419A (es) * 2003-03-28 2006-05-31 Pharmasset Inc Compuestos para el tratamiento de infecciones por flaviviridae.
SI2604620T1 (sl) 2003-05-30 2016-10-28 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Modificirani fluorirani nukleozidni analogi
ES2351603T3 (es) * 2003-07-25 2011-02-08 Idenix Pharmaceuticals, Inc. Análogos de nucleósidos de purina para el tratamiento de enfermedades causadas por flaviridae incluyendo hepatitis c.
WO2005018330A1 (fr) * 2003-08-18 2005-03-03 Pharmasset, Inc. Regime de dosage pour therapie contre flaviviridae
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
CA2571675A1 (fr) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited Derives de 5-aza-7-deazapurine pour le traitement des infections avec flaviviridae
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP3109244B1 (fr) * 2004-09-14 2019-03-06 Gilead Pharmasset LLC Préparation de 2'fluoro-2 '-alkyl-substituté ou autres éventuellement substitués ribofuranosyle pyrimidines et purines et leurs dérivés
MX2008001166A (es) * 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
ES2356776T3 (es) * 2005-10-11 2011-04-13 Intermune, Inc. Compuestos y métodos para inhibir la replicación del virus de la hepatitis.
CA2634749C (fr) * 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Procede pour la preparation d'un intermediaire synthetique pour la preparation de nucleosides ramifies
MX2008013119A (es) 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20110117054A1 (en) 2007-08-27 2011-05-19 National University Corporation Nagoya University Use of ribavirin in blood coagulation disorder
EP2198870A4 (fr) 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp Activateur pour le promoteur du facteur vii de la coagulation du sang et son utilisation
US20090082414A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched viramidine
WO2009105258A1 (fr) 2008-02-22 2009-08-27 Nektar Therapeutics Al, Corporation Conjugués oligomères de nucléosides hétéropentacycliques
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
JP2011519364A (ja) * 2008-04-15 2011-07-07 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CA2740728A1 (fr) * 2008-10-15 2010-04-22 Intermune, Inc. Peptides antiviraux therapeutiques
KR101687841B1 (ko) 2008-12-09 2016-12-19 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
EP2376088B1 (fr) * 2008-12-23 2017-02-22 Gilead Pharmasset LLC Phosphoramidates de nucléosides de type 2-amino-purine 6-O-substituée
AU2009329917B2 (en) * 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
KR20110104074A (ko) * 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
AU2010298028A1 (en) * 2009-09-28 2012-04-19 Intermune, Inc. Cyclic peptide inhibitors of hepatitis C virus replication
US20110082182A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
WO2011076923A1 (fr) 2009-12-23 2011-06-30 Institut National De La Sante Et De La Recherche Medicale Inhibiteur de l'inosine monophosphate (imp) déshydrogénase et/ou de l'arn polymérase viral utile(s) pour le traitement de l'hépatite e
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2787309A1 (fr) * 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hepatite c
HUE034239T2 (en) 2010-03-31 2018-02-28 Gilead Pharmasset Llc Method for Crystallization of (S) -isopropyl 2 - (((S) (perfluorophenoxy) (phenoxy) phosphoryl) amino) propanoate \ t
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
AU2011311880B2 (en) 2010-10-08 2014-07-24 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
TW201701876A (zh) 2010-12-20 2017-01-16 吉李德科學股份有限公司 治療ｃ型肝炎病毒（ｈｃｖ）之方法
CA2752008A1 (fr) 2011-09-13 2013-03-13 Universite De Montreal Therapie combinee utilisant de la ribavirine a titre d'inhibiteur de l'elf4e
SG11201400664WA (en) 2011-09-16 2014-04-28 Gilead Pharmassett Llc Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2912047B1 (fr) 2012-10-29 2016-08-24 Cipla Limited Analogues de phosphonate antiviraux et leur procédé de préparation
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
WO2015197518A1 (fr) 2014-06-23 2015-12-30 Sanovel Ilac Sanayi Ve Ticaret A.S. Associations pharmaceutiques du sofosbuvir et de la ribavirine
EA201692515A1 (ru) 2014-06-23 2017-05-31 Сановель Илач Санайи Ве Тиджарет А.Ш. Новая фармацевтическая композиция на основе софосбувира и рибавирина
EA201692514A1 (ru) 2014-06-23 2017-04-28 Сановель Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением
NZ728072A (en) 2014-07-11 2018-06-29 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
KR20190125537A (ko) 2014-09-16 2019-11-06 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체 조정제의 고체 형태
TW201817714A (zh) 2016-08-30 2018-05-16 英商葛蘭素史密斯克藍智慧財產權有限公司 抑制3c及3cl蛋白酶之化合物及其使用方法
CN110713464B (zh) * 2019-10-31 2023-03-31 重庆大学 一种芳基1,2,4-三氮唑核苷化合物及其制备方法和应用
WO2021209563A1 (fr) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Composés destinés à être utilisés dans le traitement d'infections virales par un coronavirus associé au syndrome respiratoire

Also Published As

Publication number Publication date
EG11406A (en) 1981-06-30
IE36478L (en) 1972-12-01
IS913B6 (is) 1975-09-15
NO138805B (no) 1978-08-07
JPS53108973A (en) 1978-09-22
BG22827A3 (fr) 1977-04-20
DK143069B (da) 1981-03-23
HU167614B (fr) 1975-11-28
BE784195A (fr) 1972-11-30
JPS5387356A (en) 1978-08-01
SE405604B (sv) 1978-12-18
IL39416A (en) 1975-07-28
JPS53124271A (en) 1978-10-30
JPS5519238B2 (fr) 1980-05-24
AR199463A1 (es) 1974-09-09
HK23876A (en) 1976-04-30
IS2075A7 (is) 1973-01-02
JPS5519239B2 (fr) 1980-05-24
ES403142A1 (es) 1975-05-01
IE36478B1 (en) 1976-11-10
DK509876A (da) 1976-11-12
RO62435A (fr) 1978-03-15
US3798209A (en) 1974-03-19
DK143069C (da) 1981-11-02
SE7801925L (sv) 1978-02-20
NL7207156A (fr) 1972-12-05
FR2140126A1 (fr) 1973-01-12
JPS5395974A (en) 1978-08-22
IL39416A0 (en) 1972-07-26
MY7600203A (en) 1976-12-31
CA997756A (en) 1976-09-28
GB1353565A (en) 1974-05-22
CH614452A5 (en) 1979-11-30
LU65446A1 (fr) 1972-10-05
DD99791A5 (fr) 1973-08-20
AU4215772A (en) 1973-12-20
MC921A1 (fr) 1973-01-25
IN142290B (fr) 1977-06-18
NO138805C (no) 1978-11-15
AU461900B2 (en) 1975-06-12
SE7801926L (sv) 1978-02-20
JPS5527076B1 (fr) 1980-07-17
DE2220246A1 (de) 1972-12-14

Similar Documents

Publication Publication Date Title
AU2658571A (fr)
AU2691671A (fr)
AU3005371A (fr)
AU2485671A (fr)
AU2684071A (fr)
AU2742671A (fr)
AU2564071A (fr)
AU2894671A (fr)
AU2941471A (fr)
AU2952271A (fr)
AU2885171A (fr)
AU2836771A (fr)
AU3038671A (fr)
AU3025871A (fr)
AU2837671A (fr)
AU2963771A (fr)
AU2486471A (fr)
AU2503871A (fr)
AU2940971A (fr)
AU2938071A (fr)
AU2930871A (fr)
AU2927871A (fr)
AU2907471A (fr)
AU2854371A (fr)
AU2588771A (fr)

Legal Events

Date Code Title Description
ST Notification of lapse